MEN 1患者胰腺神经内分泌肿瘤的医学管理：病例报告
Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report.
作者信息
Mohajeri-Tehrani Mohammad Reza, Ebrahimpur Mahbube, Nasseri-Moghaddam Siavosh, Tavangar Seyed-Mohammad, Sani Mahnaz Pejman, Zandi Abdollah, Shadmehr Mohammad Behgam
机构信息
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
J Diabetes Metab Disord. 2022 Jun 29;21(2):2009-2011. doi: 10.1007/s40200-022-01067-3. eCollection 2022 Dec.
OBJECTIVES
Multiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a few studies have been published in this field.
CASE PRESENTATION
We report a young patient with MEN-1 with multiple gastric and pancreatic neuroendocrine tumors that was treated with the monthly injection of Sandostatin LAR before and After Distal Pancreatectomy and partial gastrectomy.
CONCLUSIONS
Now she is well after four years of treatment with Sandostatin LAR.
目的
1型多发性内分泌腺瘤病（MEN-1）是一种罕见的常染色体显性遗传病，在45岁之前至少会出现一种临床症状。生长抑素类似物疗法在治疗无功能性胰腺肿瘤中的价值尚不清楚，该领域仅有少数研究发表。
病例报告
我们报告了一名患有MEN-1的年轻患者，其患有多发性胃和胰腺神经内分泌肿瘤，在远端胰腺切除术和部分胃切除术前及术后每月注射善龙进行治疗。
结论
使用善龙治疗四年后，她目前状况良好。
Zotero 插件